DrugPipeline.net

Acne Vulgaris (AV) - Market Insights, Epidemiology and Market Forecast-2023; New Report Launched

DrugPipeline.net has announced the addition of “Acne Vulgaris (AV) - Market Insights, Epidemiology and Market Forecast-2023” research report to their website DrugPipeline.net

 

Bangalore, Karnataka -- (SBWIRE) -- 03/07/2017 -- Acne vulgaris is a common chronic skin disease/Disorder of pilosebaceous follicles. The disease is characterized by blockage and/or inflammation of hair follicles and their accompanying sebaceous gland. Acne develops in regions of high sebaceous gland. The disease is seen to occur mostly in adolescence. At puberty androgens due to the increase in sebum production from enlarged sebaceous glands, the glands become blocked. Propionibacterium acnes further colonise and lead to lesion production although its exact role is unclear.

"Acne Vulgaris (AV) - Market Insights, Epidemiology and Market Forecast-2023" Report provides an overview of the disease and market size of the Acne Vulgaris for the global, United States, EU5 (France, Germany, Italy, Spain and United Kingdom) and Japan for 2013-2023. It also includes global historical and forecasted epidemiological data for the Acne Vulgaris Diagnosed Cases from 2013-2023. According to Publisher, the Diagnosed cases in 7 major markets for Acne Vulgaris (AV) were 113,959,366 cases in 2013 and are expected to be 136,929,289 cases in 2023.

As per Publisher's estimation, the global market size of Acne Vulgaris (AV) was USD 5,360.1 Millions in 2013 and is expected to reach USD 14,226.3 Million by the end of 2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

Scope
- Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
- Marketed information including available prescription drugs.
- The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5 and Japan from 2013-2023.
- It also provides Market size of Acne Vulgaris (AV) for United States, EU5 and Japan from 2013 and forecasted Market size to 2023.

Spanning over 88 pages "Acne Vulgaris (AV) - Market Insights, Epidemiology and Market Forecast-2023" report covers Report Introduction, Acne Vulgaris Market Overview at a Glance, Acne Vulgaris, Overview, Market Drivers, Appendix, Report Methodology. The Report covered companies are - Valeant Pharmaceuticals, Allergan Plc, Almirall, S.A., GlaxoSmithKline, Galderma S.A., Galderma S.A., Paratek Pharmaceuticals, Allergan, Novan, Inc.

For more information Visit at: http://www.drugpipeline.net/delveinsight/acne-vulgaris-av-market-insights-epidemiology-and-market-forecast-2023

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.